Regulatory Measures Could Mitigate Coronavirus Risks In Europe
More Flexible Procedures Will Be Needed, Says Off-Patent Industry
• By David Wallace
Generate a summary of this article
Listen to this article
As part of its response to the coronavirus outbreak, the European association representing generic and biosimilar drug companies, Medicines for Europe, has set out a series of policy recommendations that it says could help to mitigate the possible risks to medicines supply.
Medicines for Europe has some ideas for averting coronavirus risks to drug supplies • Source: Shutterstock
As part of its response to the coronavirus outbreak, European off-patent industry body Medicines for Europe has set out a series of policy recommendations that it says could help to mitigate the risks of the coronavirus COVID-19 outbreak.
[Sidebar#GB149626]
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
<p>Executive Summary</p>
<p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
<p>Executive Summary<p>
<p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.